<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD05120000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P14174</UniProt_ID>
  <Seq_Length>115</Seq_Length>
  <Molecule_Weight>12476</Molecule_Weight>
  <KEGG_ID>hsa:4282</KEGG_ID>
  <Orthology_ID>K07253</Orthology_ID>
  <EBI_ID>EBI-372712</EBI_ID>
  <Function_Summary>Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.</Function_Summary>
  <Catalytic_Mechanism>Keto-phenylpyruvate = enol-phenylpyruvate.@@L-dopachrome = 5,6-dihydroxyindole-2-carboxylate.</Catalytic_Mechanism>
  <Pfam_ID>PF01187:MIF</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>5</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>5.3.3.12&lt;/ecNumber</Alias>
      <Alias>L-dopachrome isomerase</Alias>
      <Alias>Phenylpyruvate tautomerase</Alias>
      <Alias>MIF</Alias>
      <Alias>L-dopachrome tautomerase</Alias>
      <Alias>GIF</Alias>
      <Alias>Glycosylation-inhibiting factor</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Functions to control the survival, growth, differentiation and effector function of tissues and cells.</Detail>
      <Keyword>Cytokine activity</Keyword>
      <Ontology_ID>GO:0005125</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: keto-phenylpyruvate = enol-phenylpyruvate.</Detail>
      <Keyword>Phenylpyruvate tautomerase activity</Keyword>
      <Ontology_ID>GO:0050178</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: L-dopachrome = 5,6-dihydroxyindole-2-carboxylate.</Detail>
      <Keyword>Dopachrome isomerase activity</Keyword>
      <Ontology_ID>GO:0004167</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any component on the surface of a cell.</Detail>
      <Keyword>Cell surface binding</Keyword>
      <Ontology_ID>GO:0043498</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Providing the environmental signal that initiates the directed movement of a motile cell or organism towards a higher concentration of that signal.</Detail>
      <Keyword>Chemoattractant activity</Keyword>
      <Ontology_ID>GO:0042056</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively with a cytokine receptor.</Detail>
      <Keyword>Cytokine receptor binding</Keyword>
      <Ontology_ID>GO:0005126</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the geometric or structural changes within one molecule. Isomerase is the systematic name for any enzyme of EC class 5.</Detail>
      <Keyword>Isomerase activity</Keyword>
      <Ontology_ID>GO:0016853</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the formation of prostaglandins, any of a group of biologically active metabolites which contain a cyclopentane ring.</Detail>
      <Keyword>Prostaglandin biosynthetic process</Keyword>
      <Ontology_ID>GO:0001516</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.</Detail>
      <Keyword>Inflammatory response</Keyword>
      <Ontology_ID>GO:0006954</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate, frequency, or extent of the protein kinase A signaling cascade. The PKA signaling cascade is the series of reactions, mediated by the intracellular serine/threonine kinase protein kinase A, which occurs as a result of a single trigger reaction or compound.</Detail>
      <Keyword>Positive regulation of protein kinase A signaling cascade</Keyword>
      <Ontology_ID>GO:0010739</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The multiplication or reproduction of cells, resulting in the expansion of a cell population.</Detail>
      <Keyword>Cell proliferation</Keyword>
      <Ontology_ID>GO:0008283</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of multiplication or reproduction of fibroblast cells.</Detail>
      <Keyword>Positive regulation of fibroblast proliferation</Keyword>
      <Ontology_ID>GO:0048146</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of B cell proliferation.</Detail>
      <Keyword>Positive regulation of B cell proliferation</Keyword>
      <Ontology_ID>GO:0030890</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-serine.</Detail>
      <Keyword>Positive regulation of peptidyl-serine phosphorylation</Keyword>
      <Ontology_ID>GO:0033138</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency, or extent of cell cycle arrest, the process in which the cell cycle is halted during one of the normal phases.</Detail>
      <Keyword>Negative regulation of cell cycle arrest</Keyword>
      <Ontology_ID>GO:0071157</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine.</Detail>
      <Keyword>Positive regulation of peptidyl-tyrosine phosphorylation</Keyword>
      <Ontology_ID>GO:0050731</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the regulated release of cytokines from a cell or group of cells.</Detail>
      <Keyword>Positive regulation of cytokine secretion</Keyword>
      <Ontology_ID>GO:0050715</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.</Detail>
      <Keyword>Positive regulation of ERK1 and ERK2 cascade</Keyword>
      <Ontology_ID>GO:0070374</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The formation of a protein homotrimer, a macromolecular structure consisting of three noncovalently associated identical subunits.</Detail>
      <Keyword>Protein homotrimerization</Keyword>
      <Ontology_ID>GO:0070207</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals initiated by the binding of an extracellular ligand to a receptor on the surface of the target cell.</Detail>
      <Keyword>Cell surface receptor linked signaling pathway</Keyword>
      <Ontology_ID>GO:0007166</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form.</Detail>
      <Keyword>Negative regulation of gene expression</Keyword>
      <Ontology_ID>GO:0010629</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency, or extent of cell aging. Cell aging is the progression of the cell from its inception to the end of its lifespan.</Detail>
      <Keyword>Negative regulation of cell aging</Keyword>
      <Ontology_ID>GO:0090344</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.</Detail>
      <Keyword>Innate immune response</Keyword>
      <Ontology_ID>GO:0045087</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage.</Detail>
      <Keyword>Negative regulation of DNA damage response, signal transduction by p53 class mediator</Keyword>
      <Ontology_ID>GO:0043518</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency or rate of macrophage activation.</Detail>
      <Keyword>Regulation of macrophage activation</Keyword>
      <Ontology_ID>GO:0043030</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Protein involved in immunity, any immune system process that functions in the response of an organism to a potential internal or invasive threat. The vertebrate immune system is formed by the innate immune system (composed of phagocytes, complement, antimicrobial peptides, etc) and by the adaptive immune system which consists of T- and B-lymphocytes.</Detail>
      <Keyword>Immunity</Keyword>
      <Ontology_ID>KW-0391</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>78</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>37</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MPMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA</Protein_Seq>
    <DNA_Seq>ACCACAGTGGTGTCCGAGAAGTCAGGCACGTAGCTCAGCGGCGGCCGCGGCGCGTGCGTCTGTGCCTCTGCGCGGGTCTCCTGGTCCTTCTGCCATCATGCCGATGTTCATCGTAAACACCAACGTGCCCCGCGCCTCCGTGCCGGACGGGTTCCTCTCCGAGCTCACCCAGCAGCTGGCGCAGGCCACCGGCAAGCCCCCCCAGTACATCGCGGTGCACGTGGTCCCGGACCAGCTCATGGCCTTCGGCGGCTCCAGCGAGCCGTGCGCGCTCTGCAGCCTGCACAGCATCGGCAAGATCGGCGGCGCGCAGAACCGCTCCTACAGCAAGCTGCTGTGCGGCCTGCTGGCCGAGCGCCTGCGCATCAGCCCGGACAGGGTCTACATCAACTATTACGACATGAACGCGGCCAATGTGGGCTGGAACAACTCCACCTTCGCCTAAGAGCCGCAGGGACCCACGCTGTCTGCGCTGGCTCCACCCGGGAACCCGCCGCACGCTGTGTTCTAGGCCCGCCCACCCCAACCTTCTGGTGGGGAGAAATAAACGGTTTAGAGACT</DNA_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell surface</CellLocal>
      <Ontology_ID>GO:0009986</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular space</CellLocal>
      <Ontology_ID>GO:0005615</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>MIF</Gene_Name>
    <Gene_Alias>GLIF; MMIF</Gene_Alias>
    <Gene_ID>4282</Gene_ID>
    <Genbank_ACCN>NM_002415</Genbank_ACCN>
    <Protein_ACCN>NP_002406</Protein_ACCN>
    <HGNC_ID>7097</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/4282</Gene_URL>
    <UCSC_ID>uc002zyr.1</UCSC_ID>
    <EMBL_ID>ENSG00000240972</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>O43521-2</Uniprot_ID>
      <Gene_Name>BCL2L11</Gene_Name>
      <EBI_ID>EBI-526420</EBI_ID>
      <PPI_EBI_URL>EBI-372712,EBI-526420</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Rheumatoid Vasculitis</Disease_Name>
      <Disease_Detail>Rheumatoid Vasculitis</Disease_Detail>
      <Disease_DB>RHM014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/rheumatoid_vasculitis?search=MIF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Malaria</Disease_Name>
      <Disease_Detail>Malaria</Disease_Detail>
      <Disease_DB>MLR004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/malaria?search=MIF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cysticercosis</Disease_Name>
      <Disease_Detail>Cysticercosis</Disease_Detail>
      <Disease_DB>CYS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cysticercosis?search=MIF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Septic Shock</Disease_Name>
      <Disease_Detail>Septic Shock</Disease_Detail>
      <Disease_DB>SPT013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/septic_shock?search=MIF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Rheumatoid Arthritis</Disease_Name>
      <Disease_Detail>Rheumatoid Arthritis</Disease_Detail>
      <Disease_DB>RHM011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/rheumatoid_arthritis?search=MIF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ocular Cicatricial Pemphigoid</Disease_Name>
      <Disease_Detail>Ocular Cicatricial Pemphigoid</Disease_Detail>
      <Disease_DB>OCL020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ocular_cicatricial_pemphigoid?search=MIF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Persistent Mullerian Duct Syndrome, Type I</Disease_Name>
      <Disease_Detail>Persistent Mullerian Duct Syndrome, Type I</Disease_Detail>
      <Disease_DB>PRS067</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/persistent_mullerian_duct_syndrome_type_i?search=MIF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Macular Holes</Disease_Name>
      <Disease_Detail>Macular Holes</Disease_Detail>
      <Disease_DB>MCL003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/macular_holes?search=MIF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Juvenile Rheumatoid Arthritis</Disease_Name>
      <Disease_Detail>Juvenile Rheumatoid Arthritis</Disease_Detail>
      <Disease_DB>JVN010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/juvenile_rheumatoid_arthritis?search=MIF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Arthus Reaction</Disease_Name>
      <Disease_Detail>Arthus Reaction</Disease_Detail>
      <Disease_DB>ART006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/arthus_reaction?search=MIF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Tuberculosis</Disease_Name>
      <Disease_Detail>Tuberculosis</Disease_Detail>
      <Disease_DB>TBR010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/tuberculosis?search=MIF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemosiderosis</Disease_Name>
      <Disease_Detail>Hemosiderosis</Disease_Detail>
      <Disease_DB>HMS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemosiderosis?search=MIF#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Macrophage Migration Inhibitory Factor (MIF) Complexed with OXIM6 (an OXIM Derivative Not Containing a Ring in its R-group)</PDB_Title>
      <PDB_ID>2OOZ</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OOZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor.</PubMed_Title>
      <Author>Crichlow, G.V., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:23089-23095</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17526494?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Macrophage Migration Inhibitory Factor (MIF) at 1.25 A Resolution</PDB_Title>
      <PDB_ID>3DJH</PDB_ID>
      <Resolution>1.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DJH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and kinetic analyses of macrophage migration inhibitory factor active site interactions.</PubMed_Title>
      <Author>Crichlow, G.V., et al.</Author>
      <Journal>Biochemistry(2009)48:132-139</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19090677?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of macrophage migration inhibitory factor (mif) with hydroxyquinoline inhibitor 638 at 1.93a resolution</PDB_Title>
      <PDB_ID>3JSF</PDB_ID>
      <Resolution>1.93</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JSF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:6717</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19836948?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Chicago Sky Blue 6B, A Novel Inhibitor for Macrophage Migration Inhibitory Factor</PDB_Title>
      <PDB_ID>3U18</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3U18</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD05120001</ASD_Ligand>
      <PubMed_Title>A Novel Allosteric Inhibitor of Macrophage Migration Inhibitory Factor (MIF).</PubMed_Title>
      <Author>Bai, F., et al.</Author>
      <Journal>J.Biol.Chem.(2012)287:30653-30663</Journal>
      <PubMed_ID>22782901</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Macrophage Migration Inhibitory Factor Bound to an Acetaminophen Dimer Derived from NAPQI</PDB_Title>
      <PDB_ID>3DJI</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DJI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and kinetic analyses of macrophage migration inhibitory factor active site interactions.</PubMed_Title>
      <Author>Crichlow, G.V., et al.</Author>
      <Journal>Biochemistry(2009)48:132-139</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19090677?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Macrophage Migration Inhibitory Factor (MIF) complexed with Inhibitor, 4-IPP.</PDB_Title>
      <PDB_ID>3B9S</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B9S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells.</PubMed_Title>
      <Author>Winner, M., et al.</Author>
      <Journal>Cancer Res.(2008)68:7253-7257</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18794110?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>MIF Bound to a Fluorinated OXIM Derivative</PDB_Title>
      <PDB_ID>2OOW</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OOW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor.</PubMed_Title>
      <Author>Crichlow, G.V., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:23089-23095</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17526494?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of macrophage migration inhibitory factor (MIF) with thiophenepiperazinylquinolinone inhibitor at 1.86A resolution</PDB_Title>
      <PDB_ID>3L5T</PDB_ID>
      <Resolution>1.86</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L5T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1821-1824</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20185308?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN GLYCOSYLATION-INHIBITING FACTOR</PDB_Title>
      <PDB_ID>1GIF</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GIF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structure of human glycosylation-inhibiting factor is a trimeric barrel with three 6-stranded beta-sheets.</PubMed_Title>
      <Author>Kato, Y., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1996)93:3007-3010</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8610159?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Ternary Complex of Macrophage Migration Inhibitory Factor (MIF) Bound Both to 4-hydroxyphenylpyruvate and to the Allosteric Inhibitor AV1013 (R-stereoisomer)</PDB_Title>
      <PDB_ID>3IJJ</PDB_ID>
      <Resolution>1.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IJJ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD05120002</ASD_Ligand>
      <PubMed_Title>Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.</PubMed_Title>
      <Author>Cho, Y., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:11313-11318</Journal>
      <PubMed_ID>20534506</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) WITH HYDROXPHENYLPYRUVATE</PDB_Title>
      <PDB_ID>1CA7</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1CA7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity.</PubMed_Title>
      <Author>Lubetsky, J.B., et al.</Author>
      <Journal>Biochemistry(1999)38:7346-7354</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10353846?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of macrophage migration inhibitory factor (MIF) with phenylchromenone inhibitor at 1.94A resolution</PDB_Title>
      <PDB_ID>3L5R</PDB_ID>
      <Resolution>1.94</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L5R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1821-1824</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20185308?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)</PDB_Title>
      <PDB_ID>1GD0</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GD0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography.</PubMed_Title>
      <Author>Orita, M., et al.</Author>
      <Journal>J.Med.Chem.(2001)44:540-547</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11170644?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)</PDB_Title>
      <PDB_ID>1MIF</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MIF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor.</PubMed_Title>
      <Author>Sun, H.W., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1996)93:5191-5196</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8643551?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of MIF bound to a Novel Inhibitor, OXIM-11</PDB_Title>
      <PDB_ID>2OOH</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OOH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor.</PubMed_Title>
      <Author>Crichlow, G.V., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:23089-23095</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17526494?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of macrophage migration inhibitory factor (MIF) with caffeic acid at 1.9A resolution</PDB_Title>
      <PDB_ID>3HOF</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HOF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of macrophage migration inhibitory factor (MIF) with caffeic acid at 1.9A resolution</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of macrophage migration inhibitory factor (MIF) with imidazopyridazinol inhibitor at 1.80A resolution</PDB_Title>
      <PDB_ID>3L5P</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L5P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1821-1824</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20185308?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Macrophage Migration Inhibitory Factor complexed with (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole-acetic acid methyl ester (ISO-1)</PDB_Title>
      <PDB_ID>1LJT</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LJT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Tautomerase Active Site of Macrophage Migration Inhibitory factor is a Potential Target for Discovery of Novel Anti-inflammatory Agents</PubMed_Title>
      <Author>Lubetsky, J.B., et al.</Author>
      <Journal>J.Biol.Chem.(2002)277:24976-24982</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11997397?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) WITH ALANINE INSERTED BETWEEN PRO-1 AND MET-2</PDB_Title>
      <PDB_ID>1CGQ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1CGQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity.</PubMed_Title>
      <Author>Lubetsky, J.B., et al.</Author>
      <Journal>Biochemistry(1999)38:7346-7354</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10353846?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) WITH PRO-1 MUTATED TO GLY-1</PDB_Title>
      <PDB_ID>1P1G</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1P1G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity.</PubMed_Title>
      <Author>Lubetsky, J.B., et al.</Author>
      <Journal>Biochemistry(1999)38:7346-7354</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10353846?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of macrophage migration inhibitory factor (mif) with hydroxyquinoline inhibitor 708 at 1.86a resolution</PDB_Title>
      <PDB_ID>3JTU</PDB_ID>
      <Resolution>1.86</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JTU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:6717-6720</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19836948?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of macrophage migration inhibitory factor (MIF) with glycerol at 1.70A resolution</PDB_Title>
      <PDB_ID>3L5V</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L5V</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1821-1824</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20185308?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) COMPLEXED WITH INHIBITOR.</PDB_Title>
      <PDB_ID>1GCZ</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GCZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography.</PubMed_Title>
      <Author>Orita, M., et al.</Author>
      <Journal>J.Med.Chem.(2001)44:540-547</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11170644?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of macrophage migration inhibitory factor (MIF) with imidazopyrimidinylphenyl inhibitor at 1.86A resolution</PDB_Title>
      <PDB_ID>3L5S</PDB_ID>
      <Resolution>1.86</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L5S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1821-1824</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20185308?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of macrophage migration inhibitory factor (MIF) with benzothiazole inhibitor at 1.90A resolution</PDB_Title>
      <PDB_ID>3L5U</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L5U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1821-1824</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20185308?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Macrophage Migration Inhibitory Factor (MIF) Bound to the (R)-Stereoisomer of AV1013</PDB_Title>
      <PDB_ID>3IJG</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IJG</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD05120002</ASD_Ligand>
      <PubMed_Title>Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.</PubMed_Title>
      <Author>Cho, Y., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:11313-11318</Journal>
      <PubMed_ID>20534506</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of Macrophage Migration Inhibitory Factor Covalently Inhibited by PMSF Treatment</PDB_Title>
      <PDB_ID>3CE4</PDB_ID>
      <Resolution>1.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CE4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and kinetic analyses of macrophage migration inhibitory factor active site interactions.</PubMed_Title>
      <Author>Crichlow, G.V., et al.</Author>
      <Journal>Biochemistry(2009)48:132-139</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19090677?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of macrophage migration inhibitory factor (mif) with hydroxyquinoline inhibitor 707 at 1.58a resolution</PDB_Title>
      <PDB_ID>3JSG</PDB_ID>
      <Resolution>1.58</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JSG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:6717-6720</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19836948?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko00350</Pathway_ID>
      <Pathway_Title>Tyrosine metabolism</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Amino acid metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00360</Pathway_ID>
      <Pathway_Title>Phenylalanine metabolism</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Amino acid metabolism</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.big.b.d.b.html</SCOP_URL>
    <CATH_Class>Class 3: Mixed Alpha-Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1ca7</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,37,Tyr;site,96,Tyr;site,109,Trp;site,114,Phe</Site_Detail>
      <Site_Reference>Cho Y, et al. Proc Natl Acad Sci U S A. 2010,107(25):11313-11318.</Site_Reference>
      <PDB_ID>3IJG;3IJJ</PDB_ID>
      <PubMed_ID>20534506</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>5.3.2.1</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC5/3/2/1.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD05120001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05120002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05120003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05123001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05123002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>